Nina S. Kjellson - Nov 4, 2024 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Role
Director
Signature
/s/ Nancy Levenson, Attorney-in-Fact for Nina S. Kjellson
Stock symbol
TYRA
Transactions as of
Nov 4, 2024
Transactions value $
-$194,248
Form type
4
Date filed
11/6/2024, 07:24 PM
Previous filing
Nov 1, 2024
Next filing
Nov 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TYRA Common Stock Sale -$16.3K -960 -0.03% $17.01 3.81M Nov 4, 2024 By Canaan XI L.P. F1, F2
transaction TYRA Common Stock Sale -$1.97K -116 -0.03% $17.01 458K Nov 4, 2024 By 2020+ Co-Investment L.P. - Series 7 F1, F3
transaction TYRA Common Stock Sale -$157K -9.37K -0.25% $16.77 3.8M Nov 5, 2024 By Canaan XI L.P. F2, F4
transaction TYRA Common Stock Sale -$18.9K -1.13K -0.25% $16.77 457K Nov 5, 2024 By 2020+ Co-Investment L.P. - Series 7 F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.78 to $17.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 The sole general partner of Canaan XI L.P. ("Canaan XI") is Canaan Partners XI LLC ("Canaan XI GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI. Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any.
F3 The sole general partner of Canaan 2020+ Co-Investment L.P. - Series 7 (the "Canaan Series 7") is Canaan Partners 2020+ Co-Investment LLC ("Canaan 2020+ GP"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7. Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.75 to $16.84. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.